SAB Biotherapeutics (SABS) Research & Development (2021 - 2026)
SAB Biotherapeutics (SABS) posted Research & Development of $13.4 million for Q1 2026, up 24.88% on a QoQ basis from $10.7 million in Q4 2025, and up 74.97% year-over-year from $7.7 million in Q1 2025.
SAB Biotherapeutics (SABS) Research & Development (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Research & Development history runs 6 years deep, the most recent figure standing at $13.4 million for Q1 2026.
- Quarterly Research & Development rose 74.97% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.1 million (up 33.81% YoY) and the FY2025 annual result came in at $34.4 million, up 13.56% from the prior year.
- Research & Development was $13.4 million for Q1 2026 at SAB Biotherapeutics, up from $10.7 million in the prior quarter.
- Across five years, Research & Development topped out at $13.4 million in Q1 2026 and bottomed at $3.7 million in Q2 2023.
- A 5-year average of $7.7 million and a median of $7.7 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 65.96% — and 2024, when it jumped 94.81%.
- SAB Biotherapeutics' Research & Development stood at $7.1 million in 2022, then sank by 39.8% to $4.3 million in 2023, then soared by 78.05% to $7.7 million in 2024, then jumped by 40.21% to $10.7 million in 2025, then advanced by 24.88% to $13.4 million in 2026.
- Business Quant data shows SABS's Research & Development at $13.4 million in Q1 2026, $10.7 million in Q4 2025, and $9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | SAB Biotherapeutics | 187.72 Mn | 187.72 Mn | - | 13.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.40 Mn |
| Dec 31, 2025 | 10.73 Mn |
| Sep 30, 2025 | 8.97 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Mar 31, 2025 | 7.66 Mn |
| Dec 31, 2024 | 7.65 Mn |
| Sep 30, 2024 | 7.83 Mn |
| Jun 30, 2024 | 6.82 Mn |
| Mar 31, 2024 | 8.15 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 4.02 Mn |
| Jun 30, 2023 | 3.66 Mn |
| Mar 31, 2023 | 4.54 Mn |
| Dec 31, 2022 | 7.14 Mn |
| Sep 30, 2022 | 7.35 Mn |
| Jun 30, 2022 | 8.58 Mn |
| Mar 31, 2022 | 13.32 Mn |
| Dec 31, 2021 | 10.65 Mn |
| Sep 30, 2021 | 15.07 Mn |
| Jun 30, 2021 | 18.68 Mn |